Table 1 Patients' leukemia and transplant characteristics

From: Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens

  Study population (N=31) FB2A1 group (n=18) FB1A2 group (n=13) P
Median age (years), range 55 (22–64) 51 (26–60) 57 (22–64) 0.02
Gender (male) 11 (36%) 7 (39%) 4 (31%) NS
AML category
De novo AML 25 (81%) 15 (83%) 10 (77%) NS
 Secondary AML 6 (19%) 3 (17%) 3 (23%)  
FAB classification
 M0-M6-M7 4 (13%) 2 (11%) 2 (15%)  
 M1-M2 21 (68%) 10 (56%) 11 (85%) NS
 M4-M5 6 (19%) 6 (33%) 0 (0%)  
Cytogenetics     
 Favorable 1 (3%) 0 1 (8%)  
 Intermediate 23 (74%) 15 (83%) 8 (61%) NS
 Poor 7 (23%) 3 (17%) 4 (31%)  
Number of induction cycles before CR1
 One 23 (74%) 14 (78%) 9 (69%) NS
 Two or more 8 (26%) 4 (22%) 4 (31%)  
High-dose Ara-C cycles before allo-SCT 27 (87%) 17 (94%) 10 (77%) NS
Auto-SCT before allo-SCT 12 (39%) 12 (67%) 0 0.0007
  1. Abbreviation: allo-SCT=allogeneic SCT.
  2. In the FB2A1 group, patients received a standard induction chemotherapy with daunorubicin and Ara-C. Patients who failed to enter CR after the induction chemotherapy received salvage induction chemotherapy with idarubicin and standard dose Ara-C. All the patients who achieved CR1 and the post-remission therapy consisted in a first course of daunorubicin and s.c. Ara-C. Then, patients usually received one cycle of high-dose Ara-C followed by an autologous SCT. In the FB1A2 group, all patients but one received an induction therapy comprising an anthracycline (daunorubicin, idarubicin or mitoxantrone) and standard dose Ara-C. One patient received a high-dose Ara-C course only as induction therapy. Patients achieving CR1 were scheduled to receive a post-remission therapy consisting of idarubicin and low-dose s.c. Ara-C followed by one course of high-dose Ara-C. No autologous SCT was performed in this cohort. In the FB1A2 group, one patient with favorable cytogenetics (namely t(8;21)) was transplanted in CR1 because of persistent aplasia following a high-dose Ara-C.